STENTYS® offers innovative solutions to the interventional cardiologist to treat patients with acute myocardial infarction and other complex coronary disease. The STENTYS product portfolio consists of the Self-Apposing® STENTYS BMS and DES(P) stents and the aspiration catheter STENTYS AC.
With offices in France (Paris) and in the USA (Princeton, New Jersey), STENTYS became listed on the Paris EuroNext stock exchange (STNT.PA) in October 2010. STENTYS® received CE-Marking for its BMS and DES(P) stents in early 2010 and currently sells its products in more than 8 European countries.
The STENTYS Clinical Program includes both randomised trials and real-life registries, evaluating the STENTYS stent in STEMI with the APPOSITION program, and in bifurcations with the OPEN program. STENTYS has started a 3,000 patient post-market registry in 2012 to examine the real-world use of the STENTYS stent where stent sizing is a concern.
The history of STENTYS and the path it has followed from the time it was founded in 2006 until today can be seen below:
THE STENTYS JOURNEY :